TeMac™ ameliorates memory impairment and cholinergic dysfunction in rats induced by scopolamine

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by cognitive impairments linked to cholinergic dysfunction.
• Scopolamine-induced cognitive deficits in rats serve as a model for studying AD-related memory loss.

Purpose of the Study:

• To evaluate TeMac™'s efficacy in preventing memory impairment in a scopolamine-induced rat model of AD.
• To identify TeMac™'s active compounds and their potential to inhibit acetylcholinesterase using in silico methods.

Main Methods:

• Cognitive function was assessed using the Morris Water Maze and novel object recognition tests.
• Cholinesterase activity, histopathology, and TeMac™ composition were analyzed.
• In silico molecular docking was used to predict blood-brain barrier penetration and acetylcholinesterase inhibition.

Main Results:

• TeMac™ administration significantly prevented memory deficits and reduced cholinesterase activity in rats.
• Histopathological analysis showed TeMac™ protected against neuronal loss and morphological alterations in the hippocampus.
• Seven compounds were identified in TeMac™, with oleaterminaloic acid B and stigmasterol showing potential for blood-brain barrier crossing and acetylcholinesterase inhibition.

Conclusions:

• TeMac™ demonstrates potential in preventing and managing cognitive impairments in Alzheimer's disease.
• The compound's mechanism involves reducing cholinesterase activity and protecting hippocampal neurons.
• Identified active compounds offer a basis for developing new therapeutic strategies for AD.